Literature DB >> 28191510

Aspirin resistance in coronary heart disease: Current understandings and strategies.

Ya-Ling Han1.   

Abstract

Entities:  

Year:  2016        PMID： 28191510      PMCID： PMC5290907          DOI： 10.1515/jtim-2016-0002

Source DB:  PubMed          Journal:  J Transl Int Med        ISSN： 2224-4018


× No keyword cloud information.
  20 in total

1.  Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.

Authors:  Kenneth W Mahaffey; Daniel M Wojdyla; Kevin Carroll; Richard C Becker; Robert F Storey; Dominick J Angiolillo; Claes Held; Christopher P Cannon; Stefan James; Karen S Pieper; Jay Horrow; Robert A Harrington; Lars Wallentin
Journal:  Circulation       Date:  2011-06-27       Impact factor: 29.690

Review 2.  Cardiovascular pharmacogenetics of anti-thrombotic agents and non-steroidal anti-inflammatory drugs.

Authors:  J Stitham; P Vanichakarn; L Ying; J Hwa
Journal:  Curr Mol Med       Date:  2014       Impact factor: 2.222

3.  Aspirin resistance: possible roles of cardiovascular risk factors, previous disease history, concomitant medications and haemorrheological variables.

Authors:  Gergely Feher; Katalin Koltai; Elod Papp; Balint Alkonyi; Alexander Solyom; Peter Kenyeres; Gabor Kesmarky; Laszlo Czopf; Kalman Toth
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

4.  Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease.

Authors:  Andrew O Maree; Ronan J Curtin; Michelle Dooley; Ronan M Conroy; Peter Crean; Dermot Cox; Desmond J Fitzgerald
Journal:  J Am Coll Cardiol       Date:  2005-10-04       Impact factor: 24.094

5.  Low-dose aspirin increases aspirin resistance in patients with coronary artery disease.

Authors:  Pui-Yin Lee; Wai-Hong Chen; William Ng; Xi Cheng; Jeanette Yat-Yin Kwok; Hung-Fat Tse; Chu-Pak Lau
Journal:  Am J Med       Date:  2005-07       Impact factor: 4.965

6.  Increased platelet expression of glycoprotein IIIa following aspirin treatment in aspirin-resistant but not aspirin-sensitive subjects.

Authors:  Christopher N Floyd; Timothy Goodman; Silke Becker; Nan Chen; Agnesa Mustafa; Emma Schofield; James Campbell; Malcolm Ward; Pankaj Sharma; Albert Ferro
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

7.  Aspirin noncompliance is the major cause of "aspirin resistance" in patients undergoing coronary stenting.

Authors:  Thomas Cuisset; Corinne Frere; Jacques Quilici; Bénédicte Gaborit; Laurent Bali; Raphaël Poyet; Dorothée Faille; Pierre Emmanuel Morange; Marie-Christine Alessi; Jean-Louis Bonnet
Journal:  Am Heart J       Date:  2009-05       Impact factor: 4.749

8.  Platelet glycoprotein IIIa gene polymorphism (Leu33Pro) and aspirin resistance in a very elderly Chinese population.

Authors:  Bei-Yun Wang; Shi-Jin Tan
Journal:  Genet Test Mol Biomarkers       Date:  2014-04-10

9.  Relation of aspirin response to age in patients with stable coronary artery disease.

Authors:  Mordehay Vaturi; Muthiah Vaduganathan; Tamir Bental; Alejandro Solodky; Ran Kornowski; Eli I Lev
Journal:  Am J Cardiol       Date:  2013-04-06       Impact factor: 2.778

10.  A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.

Authors:  Patricia A Gum; Kandice Kottke-Marchant; Patricia A Welsh; Jennifer White; Eric J Topol
Journal:  J Am Coll Cardiol       Date:  2003-03-19       Impact factor: 24.094
View more
  4 in total

1.  COX-1, COX-2 and CYP2C19 variations may be related to cardiovascular events due to acetylsalicylic acid resistance.

Authors:  Deniz Kirac; Aysun Erdem Yaman; Tansu Doran; Mujgan Mihmanli; Elif Cigdem Keles
Journal:  Mol Biol Rep       Date:  2022-01-09       Impact factor: 2.316

2.  Targeting aspirin resistance with nutraceuticals: a possible strategy for reducing cardiovascular morbidity and mortality.

Authors:  James J DiNicolantonio; James H O'Keefe; Mark F McCarty
Journal:  Open Heart       Date:  2017-09-02

3.  Predictors of high on-aspirin platelet reactivity in elderly patients with coronary artery disease.

Authors:  J W Zhang; W W Liu; Timothy A McCaffrey; X Q He; W Y Liang; X H Chen; X R Feng; Sidney W Fu; M L Liu
Journal:  Clin Interv Aging       Date:  2017-08-10       Impact factor: 4.458

Review 4.  Multifactorial Background for a Low Biological Response to Antiplatelet Agents Used in Stroke Prevention.

Authors:  Adam Wiśniewski
Journal:  Medicina (Kaunas)       Date:  2021-01-10       Impact factor: 2.430
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.